Lincoln Financial Enhances Fixed Indexed Annuities With New Cap Lock Strategy and Exclusive Nasdaq Priva™ Index
'In today's market environment, investors want more options for predictable growth and protection from volatility to help them feel confident in their financial plan. FIAs inherently offer full protection when markets are down, and Lincoln's new Cap Lock strategy adds certainty by locking-in their cap for the duration of the term for when markets are up, giving investors greater assurance in their investment outcome,' said Dan Herr, SVP, annuity product management at Lincoln Financial. 'With our latest FIA innovations, Lincoln continues to focus on meeting the needs of consumers as we accelerate our strategic focus on growing spread-based businesses.'
New features include:
The 1 Year S&P 500 Cap Lock account offers investors growth up to the cap, which is 'locked in' for multiple years, when index performance is positive, and 100% downside protection when the index performance is negative. Locking in the cap rate helps investors balance stability and growth opportunities.
The 1 Year Nasdaq Priva™ Participation account allows investors to participate in the upside potential of innovation-driven and new economy equity growth with downside protection. The Nasdaq Priva™ Index is a core equity-only strategy that aims to provide access to innovative, growth-oriented equities, and is designed to adapt to changing regimes in inflation and interest rates.
'The Nasdaq Priva™ Participation account provides investors with opportunities for greater upside growth in positive markets and diversification with highly experienced asset management — exclusively through a Lincoln FIA,' said Tim Seifert, SVP, head of retirement solutions distribution at Lincoln Financial. 'With Lincoln's new FIA strategies, financial professionals can provide clients with more choices for growth without sacrificing protection.'
To learn more about the competitive features and benefits of Lincoln FIAs, visit: www.LincolnFinancial.com
To learn more about our latest enhancements, view the resources below:
Cap Lock account flyer
Nasdaq Priva™ Index flyer
Editor's note: Lincoln executives celebrated the launch of the Nasdaq Priva™ Index at the Nasdaq Tower in Times Square today. High-resolution photos are available upon request.
Lincoln OptiBlend ® fixed indexed annuities (contract form ICC1515-619 and state variations) are issued by The Lincoln National Life Insurance Company, Fort Wayne, IN, and distributed by Lincoln Financial Distributors, Inc., a broker-dealer. The Lincoln National Life Insurance Company does not solicit business in the state of New York, nor is it authorized to do so. Contractual obligations are subject to the claims-paying ability of The Lincoln National Life Insurance Company.
About Lincoln Financial
Lincoln Financial helps people confidently plan for their vision of a successful financial future. As of December 31, 2024, approximately 17 million customers trust our guidance and solutions across four core businesses – annuities, life insurance, group protection, and retirement plan services. As of June 30, 2025, the company had $331 billion in end-of-period account balances, net of reinsurance. Headquartered in Radnor, PA., Lincoln Financial is the marketing name for Lincoln National Corporation (NYSE: LNC) and its affiliates. Learn more at LincolnFinancial.com.
**Photo assets available
LCN-8188956-071825
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
S&P 500 Gains and Losses Today: Solar Stocks Surge; Intel Slides After Recent Rally
Key Takeaways The S&P 500 was little changed Monday, Aug. 18, 2025, ahead of results from major retailers set for release this week and a key speech by the Federal Reserve chair Friday. Shares of HR software provider Dayforce surged following reports that a private equity firm was evaluating a potential buyout. Intel shares slipped, bringing their recent rally to a halt as more details emerged about the U.S. government's interest in acquiring a stake in the chipmaker. Major U.S. equities indexes were little changed Monday ahead of key retail sector earnings reports and comments from Federal Reserve Chair Jerome Powell expected later in the week. The S&P 500 and the Dow ended Monday's session fractionally lower, while the Nasdaq eked out a 0.03% gain. All three finished the session just short of record highs. Dayforce (DAY) shares skyrocketed 26%, securing the S&P 500's top performance on Monday, following reports that private equity firm Thoma Bravo is discussing a potential buyout of the human resources software provider. A deal could within the next few weeks, according to Bloomberg. First Solar (FSLR) shares jumped 9.7%. Other solar Solar stocks also surged, after the U.S. Treasury Department issued guidance on the types of projects that can qualify for clean energy tax credits. Although the latest guidelines limit eligible projects, analysts suggested the new rules are less restrictive than investors previously feared. Shares of The Trade Desk (TTD) rose 5.4%, extending Friday's gains after the provider of tools to help advertisers optimize their digital campaigns stressed the strength of its partnership with Walmart. Reports that the retail giant had ended an exclusive arrangement with The Trade Desk had added to concerns surrounding the stock, which tumbled earlier this month after the company warned tariffs are limiting big ad spending. EQT Corp. (EQT) shares dropped 4.4%, falling the most of any stock in the S&P 500, after Roth Capital downgraded the stock and three of its peers in the natural gas business to "neutral" from "buy." Analysts voiced concerns an oversupply of natural gas could pressure prices and hurt EQT's results. Roth Capital maintained a "buy" rating on Coterra Energy (CTRA) but reduced its price target on the stock, and Coterra shares slipped 3.3%. Intel (INTC) shares lost 3.7%, halting their recent rally amid speculation it could win more government support as more details emerged about the talks. Bloomberg reported Monday that the Trump administration is considering taking a 10% stake, and converting some or all of the company's CHIPS Act grants into equity. Shares of videogame maker Electronic Arts (EA) slid 3.2% on Monday. Since notching a record high last week, bolstered by optimism surrounding its upcoming title Battlefield 6, EA stock has been trending lower. Analysts have expressed concerns about the lofty expectations for Battlefield 6 as well as challenges facing the company's American Football franchise. Read the original article on Investopedia Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
10 minutes ago
- Business Wire
Essential Properties Realty Trust, Inc. Announces Pricing of $400 Million of 5.400% Senior Notes due 2035
PRINCETON, N.J.--(BUSINESS WIRE)--Essential Properties Realty Trust, Inc. (NYSE: EPRT; the 'Company') announced today that its operating partnership, Essential Properties, L.P. (the 'Operating Partnership'), has priced a public offering of $400 million aggregate principal amount of 5.400% Senior Notes due 2035 (the 'Notes'). The Notes were priced at 98.317% of the principal amount and will mature on December 1, 2035. The offering is expected to settle on August 21, 2025, subject to the satisfaction of customary closing conditions. The Notes will be fully and unconditionally guaranteed by the Company. The Operating Partnership intends to use the net proceeds from the offering (i) to repay amounts outstanding under its revolving credit facility and (ii) for general corporate purposes, including funding future investment activity. Wells Fargo Securities, Mizuho, BMO Capital Markets, BofA Securities, Capital One Securities, TD Securities and Truist Securities are acting as joint book-running managers for the offering. Barclays, BNP PARIBAS, Citigroup, Citizens Capital Markets, Goldman Sachs & Co. LLC, Huntington Capital Markets, Morgan Stanley, Regions Securities LLC, Scotiabank, Stifel and Wolfe Capital Markets and Advisory are acting as co-managers for the offering. The offering is being made pursuant to an effective shelf registration statement filed by the Company and the Operating Partnership with the Securities and Exchange Commission (the 'SEC'). A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. When available, a copy of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Wells Fargo Securities, LLC, 608 2nd Avenue South, Suite 1000, Minneapolis, MN 55402, Attention: WFS Customer Service, toll-free at 1-800-645-3751; or Mizuho Securities USA LLC, Attention: Debt Capital Markets, 1271 Avenue of the Americas, New York, NY 10020, at 1-866-271-7403, or by visiting the EDGAR database on the SEC's web site at This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. When used in this press release, the words 'expect' and 'will,' or the negative of these words, or similar words or phrases that are predictions of or indicate future events and that do not relate solely to historical matters, are intended to identify forward-looking statements. You can also identify forward-looking statements by discussions regarding strategy, plans or intentions. Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise. The Company does not guarantee that the transactions and events described will happen as described (or that they will happen at all). You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. While forward-looking statements reflect the Company's good faith beliefs, they are not guarantees of future performance. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. In light of these risks and uncertainties, the forward-looking events discussed in this press release might not occur as described, or at all. Additional information concerning factors that could cause actual results to differ materially from these forward-looking statements is contained from time to time in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. Copies of each filing may be obtained from the Company or the SEC. Such forward-looking statements should be regarded solely as reflections of the Company's current plans and estimates. Actual results may differ materially from what is expressed or forecast in this press release. About Essential Properties Realty Trust, Inc. Essential Properties Realty Trust, Inc. is an internally managed real estate investment trust that acquires, owns and manages primarily single-tenant properties that are net leased on a long-term basis to companies operating service-oriented or experience-based businesses. As of June 30, 2025, the Company's portfolio consisted of 2,190 freestanding net lease properties with a weighted average lease term of 14.3 years and a weighted average rent coverage ratio of 3.4x. In addition, as of June 30, 2025, the Company's portfolio was 99.6% leased to tenants operating 606 different concepts across 48 states.
Business Wire
10 minutes ago
- Business Wire
Cybin Announces Results of Annual Meeting of Shareholders
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the ' Meeting '). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below: 1. Appointment of Auditor Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below: 2. Number of Directors The special resolution to set the number of directors of Cybin at six was approved by at least two-thirds of the votes casts by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below: 3. Election of Directors Each of the nominees for election as director listed in Cybin's management information circular dated July 14, 2025 were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. Voting results are set out below: George Tziras did not stand for re-election as a director. The Company thanks Mr. Tziras for his past service. About Cybin Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2025 and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
